Date of event
-
Continuing Education Credits
CME
ABIM MOC
Add to Calendar 2020-09-25 09:00:00 2020-09-26 15:30:00 Emerging Topic Conference - Intrahepatic Cholangiocarcinoma: The Next Horizon AASLD alonzo.tolver@boldrstrategy.com America/New_York public

UPDATE: The 2020 AASLD Emerging Topic Conference originally set to be a live event is now a live streaming online course set for September 25 – 26, 2020. The conference will be available for live streaming access in AASLD’s online educational portal, LiverLearning®. All times displayed for the conference are in ET.

Course Description / Needs Statement

The Emerging Topic Conference – Intrahepatic Cholangiocarcinoma: The Next Horizon – will focus on the basic, translational and clinical aspects of intrahepatic cholangiocarcinoma (iCCA). Emerging molecular technologies provide platforms to better unravel the molecular pathogenesis of iCCA, and the role of the tumor immune microenvironment. This conference will review these advances in pathogenesis iCCA, its clinical management and future challenges, with an emphasis on addressing unmet clinical needs.

Program Chairs

  • Mario Strazzabosco, MD, PhD, FAASLD
  • Gregory J. Gores, MD, FAASLD

Registration Pricing

  • Member $125
  • Trainee & Assoc. Members $50
  • Student Member $50
  • Non-Member $250
    Any physician, scientist, or researcher with doctoral-level training who is not employed by Industry (pharma/device/etc.)
  • Trainee & Assoc. Non-Member $100
    Any physician, scientist or researcher in a training program as certified by the director of their training program. This category also includes, but is not limited to, the degrees of MS, NP, PA, RN, and other related or comparable degrees.
  • Student Non-Member $100
  • Industry $350
    Any Industry (pharma/device/etc.) employee with or without medical training.

Cancellation Policy

Requests for cancellations must be submitted in writing to meetings@aasld.org.

Cancellations received through September 24, 2020 at 11:59 pm ET are subject to a 25% cancellation fee.

Cancellations received on September 25, 2020 and after are non-refundable.

Session I: Disease Burden and Trends in iCCA: The Tip of the Iceberg
Moderators: Gregory J. Gores, MD, FAASLD and Mario Strazzabosco, MD, PhD, FAASLD

  • 9:00 am – 9:05 am ET
    Introduction
    Gregory J. Gores, MD, FAASLD and Mario Strazzabosco, MD, PhD, FAASLD
  • 9:05 am – 9:25 am ET
    Epidemiological Impact and Risk Factors of iCCA
    Jill Koshiol, PhD
  • 9:25 am – 9:45 am ET
    Histological Classification of CCA Including Combined Histology Liver Cancers
    Valerie Paradis, MD, PhD
  • 9:45 am – 10:30 am ET
    State of the Art Lecture: Molecular Pathogenesis of iCCA
    Gregory J. Gores, MD, FAASLD
  • 10:30 am – 11:00 am ET
    Break

Session II: Genomic and Experimental Models
Moderators: Gregory J. Gores, MD, FAASLD and Mario Strazzabosco, MD, PhD, FAASLD

  • 11:00 am – 11:20 am ET
    Genomic Profiling and Molecular Classification: Clinical Impact
    Daniela Sia, PhD
  • 11:20 am – 11:40 am ET
    New Preclinical Models: Mice, PDX, Organoids Cellular Plasticity and Tumor Development
    Florin M. Selaru, MD
  • 11:40 am – 12:00 pm ET
    IDH, FGF2, EGFR Mutant iCCA
    Nabeel M. Bardeesy, PhD
  • 12:00 pm – 12:20 pm ET
    Non-coding RNA in iCCA
    Tushar Patel, MBChB, FAASLD
  • 12:30 pm – 1:30 pm ET
    "Brown Bag" Lunch Moderated Discussions
  • 1:30 pm – 2:00 pm ET
    Break

Session III: Tumor Microenvironment and Novel Target
Moderators: Gregory J. Gores, MD, FAASLD and Mario Strazzabosco, MD, PhD, FAASLD

  • 2:00 pm – 2:20 pm ET
    Mechanisms of ICC Invasion Targeting Cancer Associated Fibroblasts and the Tumor Associated Stroma
    Luca Fabris, MD, PhD
  • 2:20 pm – 2:40 pm ET
    Tumor Immune Microenvironment and Therapeutic Implications
    Sumera H. Rizvi, MD
  • 2:40 pm – 3:00 pm ET
    Tumor Immune Microenvironment and the Microbiome
    Tim Greten, MD
  • 3:00 pm – 3:45 pm ET
    "Happy Hour" – Moderated Session III Discussion

Session IV: Management of Patients with Early iCCA
Moderators: Gregory J. Gores, MD, FAASLD and Mario Strazzabosco, MD, PhD, FAASLD

  • 9:00 am – 9:20 am ET
    Surgical Resection
    Umberto Cillo, MD
  • 9:20 am – 9:40 am ET
    Locoregional Treatment: What is the Evidence?
    David C. Madoff, MD
  • 9:40 am – 10:00 am ET
    Is There a Role for Radiation Oncology?
    Laura Dawson, MD, FRCPC
  • 10:00 am – 10:20 am ET
    Transplantation for Small iCCA: Is this an Option?
    Julie Heimbach, MD, FAASLD
  • 10:20 am – 10:50 am ET
    Break

Session V: Systemic Therapies for Advanced ICC: Future Prospects
Moderators: Gregory J. Gores, MD, FAASLD and Mario Strazzabosco, MD, PhD, FAASLD

  • 10:50 am – 11:10 am ET
    Standard Systemic Treatment for iCCA
    Mitesh Borad, MD
  • 11:10 am – 11:30 am ET
    Beyond Conventional Chemotherapy: Any Role for Molecular Therapies or Immune-Based Approaches
    Andrew X. Zhu, MD, PhD
  • 11:30 am – 11:50 am ET
    Clinical Trial Design in ICCA: Lessons Learned From HCC
    Josep M. Llovet, MD, FAASLD
  • 11:50 am – 12:10 pm ET
    Neoadjuvant Chemotherapy for iCCA with High Risk Oncological Features
    Shishir K. Maithel, MD
  • 12:30 pm – 1:30 pm ET
    "Brown Bag" Lunch Moderated Discussions
  • 1:30 pm – 2:00 pm ET
    Break

Session VI: Patient Advocacy and ICC Consortia
Moderators: Gregory J. Gores, MD, FAASLD and Mario Strazzabosco, MD, PhD, FAASLD

  • 2:00 pm – 2:20 pm ET
    The Cholangiocarcinoma Foundation
    Stacie Lindsey
  • 2:20 pm – 2:40 pm ET
    The European Network for the Study of CCA
    Jesus Banales, PhD
  • 2:45 pm – 3:30 pm ET
    "Happy Hour" – Session VI Moderated Discussion

Needs Statement

This Emerging Topic Conference focuses on the basic, translational and clinical aspects of intrahepatic cholangiocarcinoma (iCCA). Emerging molecular technologies provide platforms to better unravel the molecular pathogenesis of iCCA, and the role of the tumor immune microenvironment. This conference will review these advances in pathogenesis iCCA, its clinical management and future challenges, with an emphasis on addressing unmet clinical needs.

Learning Objectives

Upon completion of this activity, learners will be able to:

  • The conference will formulate a state-of-the-art review of recent research and treatment advances in iCCA, with particular emphasis on present and future and treatment opportunities.
  • The conference will define and reconcile current areas of controversy.
  • The conference will delineate future avenues of research and highlight translational opportunities for novel therapies in iCCA.

Target Audience

  • Hepatologists
  • Gastroenterologists
  • Nurses
  • Nurse Practitioners
  • Physician Assistants
  • Transplant Coordinators
  • Surgeons
  • Fellows/Trainees
  • Medical Oncologists

This activity was planned in the context of the following ACGME/IOM/IPEC competencies:

  • Evidence-based Practice
  • Medical Knowledge
  • Interpersonal and Communication Skills
  • Roles/Responsibilities
  • Work in Interdisciplinary Teams

Credits Offered

  • Continuing Medical Education (CME): 11.00 AMA PRA Category 1 Credits™
  • Maintenance of Certification (MOC): 11.00 ABIM MOC Points

Accreditation and Designation Statements

Continuing Medical Education (CME)

The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Claiming CME Credits and ABIM MOC Points

CME Credits
Physicians and other health care professionals seeking AMA PRA Category 1 Credits™ for this live continuing medical education activity must complete an evaluation by Thursday, October 15. The CME evaluation will be available to you upon completion of the live streaming conference.

MOC Points
Physicians seeking ABIM and/or ABP MOC points must complete the CME and MOC evaluation by Thursday, October 15. Requests for MOC after this date will not be honored. The MOC evaluation is included in the CME evaluation.

MOC Points will be reported to the ABIM by the end of October 2020 for attendees who successfully complete the MOC evaluation.